by Richard Daverman, PhD
January 19, 2013 -- Stryker Corporation of the US will acquire a China orthopedic maker, Trauson Holdings, for $764 million in cash; Sanjiu Medical & Pharma acquired a 97% interest in Guilin Tianhe Pharma, an OTC patch products company; China National Biotec, the largest biotech in China, is reported to be planning a $1.5 billion Hong Kong IPO; Yunnan Walvax Biotech paid $49.2 million to acquire a 58% stake in Shanghai Zerun Biotech; Nanjing Micro-Tech, a medical device maker, received an equity investment from Actis; China’s SFDA is considering -reaching changes to its drug approval that will prioritize innovative drugs; Shenzhen Neptunus Bioengineering filed an application for a US Phase II clinical trial of Polydatin Injection; and Sihuan Pharma received SFDA approval to begin producing an opioid receptor inhibitor. More details….
Stock Symbols: (NYSE: SYK) (HK: 0325) (SHE: 000999) (SHE: 300142) (SHE: 000078) (HK: 0460)
